GeoVax Labs, Inc. (NASDAQ:GOVX) Receives $14.20 Consensus Target Price from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $14.20.

A number of analysts have recently commented on GOVX shares. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. D. Boral Capital reissued a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research note on Friday, January 31st. Finally, Alliance Global Partners started coverage on GeoVax Labs in a report on Monday, November 11th. They set a “buy” rating and a $15.00 price target for the company.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX opened at $1.68 on Wednesday. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The firm has a 50-day moving average of $2.08 and a 200 day moving average of $2.67.

Institutional Trading of GeoVax Labs

Large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC bought a new stake in shares of GeoVax Labs in the 4th quarter valued at approximately $104,000. Northern Trust Corp bought a new position in shares of GeoVax Labs during the 4th quarter valued at approximately $29,000. Geode Capital Management LLC raised its holdings in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the period. Finally, Virtu Financial LLC bought a new stake in GeoVax Labs in the third quarter worth $97,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.